7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,357.88

-338.04

-0.44%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

Brussels - Delayed Quote EUR

Jensen-Group NV (JEN.BR)

72.20 -1.80 (-2.43%)

At close: October 30 at 5:35:26 PM GMT+1

Loading Chart for JEN.BR

Chart Range Bar

Interval:

In partnership with ChartIQ

3 Financial Stocks Crypto Holders May Prefer to Binance After the Hack

3 Financial Stocks Crypto Holders May Prefer to Binance After the Hack

Metsä Board Shares In Focus After Smaller Q3 Loss On Weaker Sales

Metsä Board Shares In Focus After Smaller Q3 Loss On Weaker Sales

TAKKT (XTRA:TTK) Stock Sinks As Q3 Earnings Deepen Losses

TAKKT (XTRA:TTK) Stock Sinks As Q3 Earnings Deepen Losses

Is Bayer (XTRA:BAYN) Undervalued Following Its Roundup Court Win?

Is Bayer (XTRA:BAYN) Undervalued Following Its Roundup Court Win?

How Investors May Respond To TF1 (ENXTPA:TFI) Weaker Earnings Report

How Investors May Respond To TF1 (ENXTPA:TFI) Weaker Earnings Report

What Bayer (XTRA:BAYN)'s Roundup Court Win Means For Shareholders

What Bayer (XTRA:BAYN)'s Roundup Court Win Means For Shareholders

How 'deeply intertwined' are energy companies in this stage of the AI build-out?

How 'deeply intertwined' are energy companies in this stage of the AI build-out?

SES and Air Astana Introduce Multi-orbit Inflight Connectivity on A321LR Fleet

SES and Air Astana Introduce Multi-orbit Inflight Connectivity on A321LR Fleet

Nextensa NV/SA: Information on the total number of voting rights and shares

Nextensa NV/SA: Information on the total number of voting rights and shares

VILNIAUS BALDAI AB condensed interim consolidated financial statements for the twelve months of FY2026 ended August 31, 2026

VILNIAUS BALDAI AB condensed interim consolidated financial statements for the twelve months of FY2026 ended August 31, 2026

Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids

Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids

Mobilize your Website

View Site in Mobile | Classic

Share by: